» Articles » PMID: 11083468

Localization of P32 Protein (gC1q-R) in Mitochondria and at Specific Extramitochondrial Locations in Normal Tissues

Overview
Publisher Springer
Date 2000 Nov 18
PMID 11083468
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

P32 protein, also known as the gC1q receptor for complement component C1q, is a binding protein for nuclear pre-mRNA splicing factor SF2/ASF and numerous other nuclear and cell surface proteins, yet is targeted to the mitochondrial matrix compartment where these proteins are not present. In the present study, we use immunogold electron microscopy to evaluate the subcellular distribution of P32 protein (gC1q-R) in cultured cell lines and in rat tissues embedded in the acrylic resin LR Gold. Immunogold labeling of Raji lymphoma, CHO, human fibroblasts, HeLa and B-SC-1 cells shows reactivity primarily within mitochondria. Highly specific labeling of mitochondria is also obtained in rat tissues, including adrenal gland, cerebellum, cerebral cortex, heart, kidney, liver, pituitary, pancreas, skeletal muscle, spleen, testes and thyroid. However, strong P32 (gClq-R) reactivity is also present in (i) zymogen granules, condensing vacuoles, endoplasmic reticulum, and on the cell surface of pancreatic acinar cells, (ii) on the cell surface of microvascular endothelial cells in pancreas and kidney, (iii) on the cell surface and in nuclei of splenic lymphocytes, and (iv) in the acrosome of developing spermatids in testes. Western immunoblots show that the polyclonal antibody to P32 (gC1q-R) used in this study reacts specifically with a 32-kDa protein in both purified pancreatic zymogen granules and in mitochondria, and no other proteins are reactive. These results provide evidence that P32 (gC1q-R) is a mitochondrial protein that also localizes outside mitochondria in certain cells and tissues under normal physiological conditions.

Citing Articles

RNA 5-methylcytosine marks mitochondrial double-stranded RNAs for degradation and cytosolic release.

Kim S, Tan S, Ku J, Widowati T, Ku D, Lee K Mol Cell. 2024; 84(15):2935-2948.e7.

PMID: 39019044 PMC: 11316625. DOI: 10.1016/j.molcel.2024.06.023.


The C1q and gC1qR axis as a novel checkpoint inhibitor in cancer.

Ghebrehiwet B, Zaniewski M, Fernandez A, DiGiovanni M, Reyes T, Ji P Front Immunol. 2024; 15:1351656.

PMID: 38711524 PMC: 11070495. DOI: 10.3389/fimmu.2024.1351656.


Genetic and pharmacologic p32-inhibition rescue CHCHD2-linked Parkinson's disease phenotypes in vivo and in cell models.

Tio M, Wen R, Choo C, Tan J, Chua A, Xiao B J Biomed Sci. 2024; 31(1):24.

PMID: 38395904 PMC: 10893700. DOI: 10.1186/s12929-024-01010-z.


Brown adipose tissue influences adiponectin and thyroid hormone changes during Graves' disease therapy.

Ho W, Sun L, Goh H, Thway Tint M, Sun L, Leow M Adipocyte. 2022; 11(1):389-400.

PMID: 35894647 PMC: 9336474. DOI: 10.1080/21623945.2022.2104509.


Mitochondrial Respiratory Complexes as Targets of Drugs: The PPAR Agonist Example.

Bottoni P, Pontoglio A, Scara S, Pieroni L, Urbani A, Scatena R Cells. 2022; 11(7).

PMID: 35406733 PMC: 8997591. DOI: 10.3390/cells11071169.